Palisade Bio (PALI) Earnings Analysis

Palisade Bio (PALI) next reports earnings on 2026-08-10, consensus EPS -0.05 USD. Last quarter (2026-03-23) it missed with EPS -0.04 USD vs -0.02 USD est (-100%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -1.79.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PALI next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.05 USD
Revenue estimaten/a

PALI earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-23-0.04 USD-0.02 USD-100%Miss
2025-11-10-0.38 USD-0.32 USD-18.8%Miss
2025-08-11-0.58 USD-0.48 USD-20.8%Miss
2025-05-12-0.47 USD-0.84 USD+44%Beat
2025-03-24-0.69 USD-1.99 USD+65.3%Beat
2024-08-12-3.32 USD-2.93 USD-13.3%Miss

Beat rate: 2/6 (33%) over reported quarters with consensus data.

PALI valuation and analyst view

Trailing P/E-1.79
Trailing EPS-0.11519 USD
Price / book3.13
Dividend yield0.00%
Market cap0.34B
Analyst consensusBuy (3 buy / 0 hold / 0 sell)
Avg price target4.5 USD

Related research pages

Frequently asked questions

When is Palisade Bio (PALI)'s next earnings date?

Palisade Bio is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.05 USD.

Did PALI beat earnings last quarter?

In its 2026-03-23 report, PALI posted EPS of -0.04 USD versus a -0.02 USD estimate — a miss of 100%.

What is PALI's earnings track record?

Over the last 6 reported quarters with consensus data, PALI beat estimates 2 times (33%).

What is PALI's current P/E ratio and EPS?

PALI trades at a trailing P/E of -1.79 on trailing EPS of -0.11518908308736275 USD.

What do analysts rate PALI?

Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 4.5 USD.